HHS is seeking $2 billion a year to build a worldwide disease-monitoring system, according to media reports.
The latest FDA reversal is welcome, but the episode of first denying Moderna review of its mRNA flu vaccine deserves close examination.
Between federal lawsuits, sweeping schedule changes, and states mobilizing their own legal challenges, the last few weeks have been a whirlwind. Let's dive right in.
Bhattacharya has faced criticism from career NIH scientists for policy decisions and lack of leadership.
The FDA had refused to review the original application because it said Moderna’s phase 3 study was not "adequate and well-controlled."
The guidance describes how veterinary drug makers can add duration limits for medically important antibiotics used in livestock, but critics say it doesn't go far enough.
Experts say the move will hobble the United States’ ability to respond to future infectious disease threats.
The study involves hepatitis B vaccination in Guinea-Bissau, where nearly one in five people are chronically infected with the virus.
Vermont and New York health officials are reporting their first measles cases of the year, bringing the country's total numbers of measles infections in 2026 to 910.
A federal judge has issued a temporary restraining order against the cuts, which could cost health departments in California, Colorado, Illinois, and Minnesota an estimated $600 million.
